Abiopharma

🔍 Rodgers Elliott (Director)

Company: LEVI STRAUSS & CO (LEVI)

Report Date: 2026-05-05

Detailed Transactions and Holdings:

• Acquired 215 shares of Class A Common Stock at $22.235 per share (Direct)
  Date: 2026-05-05 | Code: L | equity_swap_involved: 0 | shares_owned_after: 59,834.00 | transaction_form_type: 5 | Footnotes: F1
• Acquired 80 shares of Class A Common Stock (Direct)
  Date: 2026-05-06 | Code: A | equity_swap_involved: 0 | shares_owned_after: 59,914.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Shares were acquired pursuant to a dividend reinvestment program offered through a personal brokerage account.
• F2: Represents dividend equivalent rights (DER), each of which represents a contingent right to receive one share of the issuer's Class A Common Stock upon settlement. The DERs vest and are delivered consistent with the underlying awards to which they relate. Unvested awards and the related DERs vest as to 100% of the shares on the earlier of the day before the next Annual Stockholder Meeting or the first anniversary of the date of grant of the underlying award. Certain underlying awards are fully vested and are subject to a deferred delivery feature, these same terms apply to the related DERs.